The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Genomic profiling of smoldering myeloma identifies high- and low- risk patients
In this video, Shankara Anand, MS, Broad Institute of MIT & Harvard, Cambridge, MA, discusses genomic profiling of smoldering multiple myeloma (SMM). Mr Anand first describes SMM and the current standard of care, which tends to be a ‘wait and watch’ approach. Following this, Mr Anand emphasizes the benefits of identifying patients who are high-risk and treating them before their disease progresses to multiple myeloma (MM). To conclude, Mr Anand briefly discusses a study which conducted comprehensive genomic profiling on patients with SMM, and how this helped to more accurately identify high- and low- risk patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
